ProCE Banner Activity

REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD

Slideset Download
Conference Coverage
Data from REACH3 shows ruxolitinib significantly improves responses and symptoms at Week 24 in patients with cGVHD, and inadequate steroid response, when compared with BAT.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology